DeepMed Research

DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

GM-CSF Vaccinations After Allogeneic Blood Stem Cell Transplantation in Patients With Advanced Myeloid Malignancies

Not Applicable

Completed

Conditions: Myelodysplastic Syndrome RAEB-I or RAEB-II
Refractory CML Myeloid Blast Crisis
Refractory Acute Myeloid Leukemia

First Posted Date: 2007-01-24

Last Posted Date: 2022-02-11

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 28

Registration Number: NCT00426205

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma

Phase 2

Completed

Conditions: Mucosal Melanoma
Acral/Lentiginous Melanoma
Chronically Sun Damaged Melanomas

Interventions: Drug: Imatinib

First Posted Date: 2007-01-19

Last Posted Date: 2016-12-08

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 24

Registration Number: NCT00424515

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
H. Lee Moffitt Cancer Center, Tampa, Florida, United States

and more 2 locations

Pemetrexed in Patients With Advanced Neuroendocrine Tumors

Phase 2

Completed

Conditions: Neuroendocrine Tumors

First Posted Date: 2007-01-19

Last Posted Date: 2010-08-12

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 32

Registration Number: NCT00424723

Locations: 🇺🇸
Dana-Farber Cancer Center, Boston, Massachusetts, United States

Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM)

Phase 2

Completed

Conditions: Waldenstrom's Macroglobulinemia

Interventions: Drug: Bortezomib
Drug: Rituximab

First Posted Date: 2007-01-17

Last Posted Date: 2020-10-27

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 63

Registration Number: NCT00422799

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia

Phase 2

Completed

Conditions: Waldenstrom's Macroglobulinemia

Interventions: Drug: Perifosine

First Posted Date: 2007-01-17

Last Posted Date: 2017-12-26

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 37

Registration Number: NCT00422656

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma

Phase 2

Terminated

Conditions: Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer

Interventions: Drug: Gemcitabine
Drug: Oxaliplatin
Drug: Bevacizumab

First Posted Date: 2007-01-04

Last Posted Date: 2014-06-19

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 19

Registration Number: NCT00418093

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

RAD001 in Previously Treated Patients With Metastatic Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: RAD001

First Posted Date: 2006-12-08

Last Posted Date: 2014-08-11

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 33

Registration Number: NCT00409292

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Exercise Intervention in Women With Metastatic Breast Cancer

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Behavioral: Moderate-Intensity Exercise

First Posted Date: 2006-11-30

Last Posted Date: 2016-06-27

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 101

Registration Number: NCT00405782

Locations: 🇺🇸
Beth Isreal Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

C-TPF in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Phase 1

Completed

Conditions: Head and Neck Neoplasms

First Posted Date: 2006-11-22

Last Posted Date: 2009-11-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 29

Registration Number: NCT00402545

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Treatment of Acute Lymphoblastic Leukemia in Children

Phase 3

Completed

Conditions: Drug/Agent Toxicity by Tissue/Organ
Leukemia

Interventions: Drug: asparaginase
Drug: cyclophosphamide
Drug: cytarabine
Drug: dexrazoxane hydrochloride
Drug: dexamethasone
Drug: doxorubicin hydrochloride
Drug: leucovorin calcium
Drug: etoposide
Drug: mercaptopurine
Drug: methotrexate
Drug: pegaspargase
Drug: methylprednisolone
Drug: prednisolone
Drug: therapeutic hydrocortisone
Drug: vincristine sulfate
Radiation: radiation therapy

First Posted Date: 2006-11-17

Last Posted Date: 2024-11-27

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 800

Registration Number: NCT00400946

Locations: 🇨🇦
McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇺🇸
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, United States
🇨🇦
Centre de Recherche du Centre Hospitalier de l'Universite Laval, Sainte Foy, Quebec, Canada

and more 5 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy